beta

A

Agilent Technologies, Inc.

A

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that enable to identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment comprises activity providing active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software, and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

Market Cap: 24.5 Billion

Primary Exchange: New York Stock Exchange

Website: http://www.agilent.com

Shares Outstanding: 309 Million

Float: 308 Million

Dividend: 0.641 (0.01%)

Beta: 1.1589823672555

Sector: Health Technology

Industry: Biotechnology

Ethical Flags

Animal testing

Longest drawdown: 874 trading days

From: 2014-01-22 To: 2017-07-12

Lowest Point:

Barclays bearish on Teva, sees 14% downside risk in premarket analyst action

via: SeekingAlpha at 2019-06-11 04:46:44:000

Agilent (NYSE: A ) initiated with Overweight rating and $83 (18% upside) price target at Piper Jaffray. More news on: Agilent Technologies, Inc., Danaher Corporation, Teleflex Incorporated, Healthcare stocks news, Stocks on the move, , Read more … read more...

Barclays bearish on Teva, sees 14% downside risk in premarket analyst action

via: SeekingAlpha at 2019-06-11 04:46:44:000

Agilent (NYSE: A ) initiated with Overweight rating and $83 (18% upside) price target at Piper Jaffray. More news on: Agilent Technologies, Inc., Danaher Corporation, Teleflex Incorporated, Healthcare stocks news, Stocks on the move, , Read more … read more...

Barclays bearish on Teva, sees 14% downside risk in premarket analyst action

via: SeekingAlpha at 2019-06-11 04:46:44:000

Agilent (NYSE: A ) initiated with Overweight rating and $83 (18% upside) price target at Piper Jaffray. More news on: Agilent Technologies, Inc., Danaher Corporation, Teleflex Incorporated, Healthcare stocks news, Stocks on the move, , Read more … read more...

Agilent Companion Diagnostic Gains Expanded FDA Approval in Head and Neck Squamous Cell Carcinoma (HNSCC)

via: Business Wire at 2019-06-11 03:56:00:000

PD-L1 IHC 22C3 pharmDx can now be used as an aid to identify HNSCC patients for treatment with KEYTRUDA (pembrolizumab) Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved its PD-L1 IHC 22C3 pharmDx assay for expand… read more...

Agilent Companion Diagnostic Gains Expanded FDA Approval in Head and Neck Squamous Cell Carcinoma (HNSCC)

via: Business Wire at 2019-06-11 03:56:00:000

PD-L1 IHC 22C3 pharmDx can now be used as an aid to identify HNSCC patients for treatment with KEYTRUDA (pembrolizumab) Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved its PD-L1 IHC 22C3 pharmDx assay for expand… read more...

Agilent Companion Diagnostic Gains Expanded FDA Approval in Head and Neck Squamous Cell Carcinoma (HNSCC)

via: Business Wire at 2019-06-11 03:56:00:000

PD-L1 IHC 22C3 pharmDx can now be used as an aid to identify HNSCC patients for treatment with KEYTRUDA (pembrolizumab) Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved its PD-L1 IHC 22C3 pharmDx assay for expand… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
2019-09-30 2019-10-23 2019-10-01 2019-09-18 0.164 Cash
2019-09-30 2019-10-23 2019-10-01 2019-09-18 0.164 No Change QoQ
2019-07-01 2019-07-24 2019-07-02 2019-05-22 0.164 No Change QoQ
2019-04-01 2019-04-24 2019-04-02 2019-03-20 0.164 No Change QoQ
2018-12-28 2019-01-23 2018-12-31 2018-11-14 0.164 Increase
2018-10-01 2018-10-24 2018-10-02 2018-09-19 0.149 No Change QoQ
2018-07-02 2018-07-25 2018-07-03 2018-05-16 0.149 No Change QoQ
2018-04-02 2018-04-25 2018-04-03 2018-03-21 0.149 No Change QoQ
2017-12-29 2018-01-24 2018-01-02 2017-11-15 0.149 Increase
2017-10-02 2017-10-25 2017-10-03 2017-09-20 0.132 No Change QoQ
2017-06-29 2017-07-26 2017-07-03 2017-05-17 0.132 No Change QoQ
2017-03-31 2017-04-26 2017-04-04 2017-03-15 0.132 No Change QoQ
2016-12-29 2017-01-25 2017-01-03 2016-11-17 0.132 Increase
2016-09-30 2016-10-26 2016-10-04 2016-09-21 0.115 No Change QoQ
2016-06-30 2016-07-27 2016-07-05 2016-05-18 0.115 No Change QoQ
2016-04-01 2016-04-27 2016-04-05 2016-03-16 0.115 No Change QoQ
2015-12-31 2016-01-27 2016-01-05 2015-11-19 0.115 Increase
2015-09-25 2015-10-21 2015-09-29 2015-09-16 0.1 No Change QoQ
2015-06-26 2015-07-22 2015-06-30 2015-05-20 0.1 No Change QoQ
2015-03-27 2015-04-22 2015-03-31 2015-03-18 0.1 No Change QoQ
2015-01-02 2015-01-28 2015-01-06 2014-11-20 0.1 Decrease
2014-09-26 2014-10-22 2014-09-30 2014-09-17 0.132 No Change QoQ
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud